Stoke Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Stoke Therapeutics, Inc. (STOK) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$2.06 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2023-11-07
- Stoke Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-09-30 was $2.02M.
- Stoke Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-06-30 was -$4.43M, a 517.64% decline year-over-year.
- Stoke Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-03-31 was $351.00K.
- Stoke Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-12-31 was $199.00K, a 94.48% decline year-over-year.
- Stoke Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$3.53M, a 221.85% decline from fiscal 2021.
- Stoke Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was $2.90M, a 44.32% decline from fiscal 2020.
- Stoke Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was $5.20M, a 483.95% increase from fiscal 2019.
- Stoke Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2019 was $891.00K, a 48.65% decline from fiscal 2018.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$2.41M derived: sum of 2 quarters · filed 2023-11-07 | -$2.06M 10-Q · filed 2023-11-07 | -$1.86M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | -$4.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$4.08M 10-Q · filed 2023-08-07 | -$3.88M derived: sum of 3 quarters · filed 2023-08-07 | -$5.22M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $351.00K 10-Q · filed 2023-05-04 | $550.00K derived: sum of 2 quarters · filed 2023-05-04 | -$796.00K derived: sum of 3 quarters · filed 2023-11-07 | $264.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$1.15M derived: sum of 2 quarters · filed 2023-11-07 | -$87.00K derived: sum of 3 quarters · filed 2023-11-07 | -$3.53M 10-K · filed 2023-03-06 |
| 2022-09-30 | -$1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$286.00K derived: sum of 2 quarters · filed 2023-11-07 | -$3.73M 10-Q · filed 2023-11-07 | -$125.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$2.38M 10-Q · filed 2023-08-07 | $1.22M derived: sum of 3 quarters · filed 2023-08-07 | $3.67M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$3.44M 10-Q · filed 2023-05-04 | $161.00K derived: sum of 2 quarters · filed 2023-05-04 | $2.61M derived: sum of 3 quarters · filed 2023-05-04 | $4.95M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $6.05M derived: sum of 2 quarters · filed 2023-03-06 | $8.40M derived: sum of 3 quarters · filed 2023-03-06 | $2.90M 10-K · filed 2023-03-06 |
| 2021-09-30 | $2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $4.79M derived: sum of 2 quarters · filed 2022-11-14 | -$707.00K 10-Q · filed 2022-11-14 | $3.66M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$3.15M 10-Q · filed 2022-08-08 | $1.22M derived: sum of 3 quarters · filed 2022-08-08 | $1.82M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$5.50M 10-Q · filed 2022-05-10 | -$1.13M derived: sum of 2 quarters · filed 2022-05-10 | -$519.00K derived: sum of 3 quarters · filed 2022-05-10 | -$285.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $4.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $4.98M derived: sum of 2 quarters · filed 2022-03-10 | $5.21M derived: sum of 3 quarters · filed 2022-03-10 | $5.20M 10-K · filed 2022-03-10 |
| 2020-09-30 | $610.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $844.00K derived: sum of 2 quarters · filed 2021-11-08 | $833.00K 10-Q · filed 2021-11-08 | -$928.00K derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $234.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $223.00K 10-Q · filed 2021-08-10 | -$1.54M derived: sum of 3 quarters · filed 2021-08-10 | $19.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$11.00K 10-Q · filed 2021-05-10 | -$1.77M derived: sum of 2 quarters · filed 2021-05-10 | -$215.00K derived: sum of 3 quarters · filed 2021-05-10 | $1.15M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | -$1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$204.00K derived: sum of 2 quarters · filed 2021-03-09 | $1.16M derived: sum of 3 quarters · filed 2021-03-09 | $891.00K 10-K · filed 2021-03-09 |
| 2019-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $2.92M derived: sum of 2 quarters · filed 2020-11-12 | $2.65M 10-Q · filed 2020-11-12 | $3.55M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.09M 10-Q · filed 2020-08-10 | $1.99M derived: sum of 3 quarters · filed 2020-08-10 | $2.43M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | -$265.00K 10-Q · filed 2020-05-15 | $632.00K derived: sum of 2 quarters · filed 2020-05-15 | $1.07M derived: sum of 3 quarters · filed 2020-05-15 | |
| 2018-12-31 | $897.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $1.33M derived: sum of 2 quarters · filed 2020-03-23 | $1.74M 10-K · filed 2020-03-23 | |
| 2018-09-30 | $436.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $838.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $402.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |